Stellar Biotechnologies uses limpets to develop medicine
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen’s new drug for migraines shows promise
Thousand Oaks-based Amgen said a drug being developed in collaboration with Novartis showed promising results in providing relief for patients suffering from chronic migraines. The Phase 2 clinical trial met benchmarks for migraine reduction at two levels of dosage and with limited side effects. “Migraine is the sixth-leading cause of disability worldwide. Three to seven Read More →
Ex-Kythera execs build Westlake Village startup
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen subsidiary discovers rare gene that could reduce heart attack risk
An Amgen subsidiary may have found a rare gene that could drastically reduce the risk of heart attacks in the future. DeCode Genetics, an Iceland-based subsidiary of Thousand Oaks biotech giant Amgen, uncovered a rare and unknown genetic variation in some people that could reduce the risk of heart attacks and lower cholesterol. The variant Read More →
Santa Barbara’s MedBridge launches surgical concierge service Kinese
Santa Barbara-based ambulatory surgery center developer MedBridge launched a new health care service that connects patients with surgeons. Kinese is described as a surgical concierge service that’s rolling out in Santa Barbara, Beverly Hills and San Francisco. It provides immediate access to surgeons and facilities, bypassing expensive and ambiguous costs, waitlists and limited access to Read More →
Sientra selling implants again but staff cut as losses mount
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Stellar Biotechnologies revenues nearly doubled in first quarter
Stellar Biotechnologies revenues nearly doubled but so did the company’s losses during the first quarter, the Port Hueneme biotech company reported May 9. Stellar Biotechnologies makes a protein for immunotherapy treatments using a unique sea snail only found off the coastal shores of a small part of California. The company’s revenues increased from $187,627 during Read More →
